Crossmark

Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer

Published Online: 2021-01-14

Published Print: 2021-12

Authors

Li, Jun

Yue, Huiran

Yu, Hailin

Lu, Xin

Xue, Xiaohong http://orcid.org/0000-0002-6498-5609
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81802596)

Natural Science Foundation of Shanghai (20ZR1408900)
License Information

Text and Data Mining valid from 2021-01-14

Version of Record valid from 2021-01-14
More Information

Article History

Received: 8 February 2020

Accepted: 2 January 2021

First Online: 14 January 2021

Ethics approval and consent to participate

: All data in this article are obtained from published studies, which have received ethics approval and consent to participate. The study was performed in accordance with the Declaration of Helsinki.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current